RVNC Revance Therapeutics Inc: Forward Price-to-Revenue Multiple

Public company logo of Revance Therapeutics (RVNC)

The injectables market is protected by toxin purification patents and a strong brand. The forward price-to-sales ratio for Revance Therapeutics (RVNC) shows a pivot driven by expansion into spasticity therapy and a bet on the longevity of Daxxify, while strictly adhering to FDA regulations on biomaterial disposal. The current level is 1.50, which captures investors' real-time assessment of the company's future revenues.

Revance Therapeutics, Inc. - RVNC Forward P/S Multiple (period 07/04/2022 - 02/16/2025)

Summary analytical data breakdowns for Revance Therapeutics (RVNC)

- current price and projected stock value:
Initial company analysis:Revance Therapeutics, Inc (RVNC)
Product sample of Revance Therapeutics Inc

Forward P/S measures the market value of a business relative to expected revenue, allowing for an assessment of whether an asset's price is overextended relative to future cash flows. Analyzing the forward P/S chart for Revance Therapeutics (RVNC) helps identify liquidity risks, as the aggressive scaling of the aesthetic injections distribution network requires colossal promotional expenditures, which temporarily offsets operating leverage and limits profitability.